論文

基本情報

氏名 加藤 正樹
氏名(カナ) カトウ マサキ
氏名(英語) KATO MASAKI
所属 中村学園大学 栄養科学部 栄養科学科
職名 教授

題名

Analysis of renal function during telaprevir-based triple therapy for chronic hepatitis C

単著・共著の別

 

著者

Motoyuki Kohjima
Miho Kurokawa
Munechika Enjoji
Tsuyoshi Yoshimoto
Tsukasa Nakamura
Tomoko Ohashi
Kunitaka Fukuizumi
Naohiko Harada
Yusuke Murata
Kazuhisa Matsunaga
Masaki Kato
Kazuhiro Kotoh
Makoto Nakamuta

担当区分

 

概要

Telaprevir (TVR) is used for the treatment of chronic hepatitis C in a combination therapy with pegylated-interferon and ribavirin. Although renal dysfunction is one of the critical adverse outcomes of this treatment, little is known regarding the mechanism of its onset. The present study assessed the association of renal function with TVR dose and viral response. Hematological, biochemical, urinary and virological parameters of renal function were examined during the TVR-based triple therapy of patients infected with hepatitis C virus (HCV) genotype 1b. Serum creatinine levels were increased and the estimated glomerular filtration rate (eGFR) was decreased in every patient during TVR administration, but these values recovered to normal levels following cessation of TVR. Fractional excretion of sodium was <1% at days 3 and 7, appearing similar regardless of baseline renal function. Urinary beta(2)-microglobulin levels were elevated and were significantly higher in patients with renal dysfunction, as compared with those not exhibiting renal dysfunction (P < 0.05). The reduction in renal function was milder in patients treated with a reduced TVR dose, and these patients had a significantly lower risk of developing renal dysfunction (P < 0.05). Using a multivariate analysis, TVR dose and eGFR at the initiation of treatment were identified as significant contributory factors in the development of renal dysfunction. Reduction in TVR dose did not lead to a significant increase in the viral kinetics of HCV or detrimental effects on the sustained viral response (SVR) rate. It is hypothesized that renal dysfunction during TVR treatment is caused by damage of the renal tubule, in addition to pre-renal dysfunction, and that reduction in TVR dose reduces the rate of renal dysfunction without causing a significant decrease in the SVR rate.

発表雑誌等の名称

EXPERIMENTAL AND THERAPEUTIC MEDICINE

出版者

SPANDIDOS PUBL LTD

11

5

開始ページ

1781

終了ページ

1787

発行又は発表の年月

2016-05

査読の有無

有り

招待の有無

無し

記述言語

英語

掲載種別

研究論文(学術雑誌)

国際・国内誌

 

国際共著

 

ISSN

 

eISSN

 

DOI

10.3892/etm.2016.3133

Cinii Articles ID

 

Cinii Books ID

 

Pubmed ID

 

PubMed Central 記事ID

 

形式

無償ダウンロード

JGlobalID

 

arXiv ID

 

ORCIDのPut Code

 

DBLP ID